-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Improving Long-Term Outcomes With Intensive Induction Chemotherapy for Patients with AML

Program: Education Program
Session: Have We Optimized Therapy Yet for Patients with AML?
Hematology Disease Topics & Pathways:
AML, Acute Myeloid Malignancies, clinical trials, Research, adult, Clinical Research, Combination therapy, Diseases, Therapies, Myeloid Malignancies, Study Population, Human
Sunday, December 10, 2023, 4:30 PM-5:45 PM

Christoph Röllig, MD, MSc

Department of Internal Medicine I, University Hospital Dresden, Dresden, Germany

Disclosures: Röllig: Servier: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Astellas: Consultancy, Honoraria.

See more of: Have We Optimized Therapy Yet for Patients with AML?
See more of: Education Program
Previous Presentation | Next Presentation >>